Breadcrumb Home Resources and Information Physicians and Scientists Resource Hub Olverembatinib As Second-Line (2L) Therapy In Patients (pts) With Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Blood , Nov 2024 Weiming L et al. Blood, November 2024 Link to full abstract Share Tweet Share Share